E-Star BioTech CEO Jesse Crowne on the recent news of dosing the first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN). Read more about our progress at e

📍 E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension Full story:

E-Star BioTech is advancing hypertension management through ongoing research. Our current clinical trials are focused on cardiovascular-metabolic-renal syndrome, aiming to better understand how our peptide therapies can impact this complex condition.Stay tuned for more.

As 2024 comes to a close, we’re reflecting on an incredible year of progress and innovation and thankful for those who have helped make 2024 extraordinary. Here’s to continued progress, and good health in 2025. We wish you a very happy New Year!

Hypertension is a major global health challenge, with many struggling to manage it despite available treatments. At E-Star BioTech, we’re dedicated to empowering patients to take control and reduce hypertension-related risks. Learn more: #Hypertension

Interesting findings from this recent trial.

The cardiac peptide hormone atrial natriuretic peptide (ANP) is the heart’s regulator of cardiovascular and metabolic function. Learn more about ANP and Modified Atrial Natriuretic Peptide (MANP) and the potential for better hypertension treatment at

E-Star BioTech is advancing hypertension management through ongoing research. Our current clinical trials are focused on cardiovascular-metabolic-renal syndrome, aiming to better understand how our peptide therapies can impact this complex condition.

Natriuretic Peptides and Metabolic Hypertension: A Match Made in Heaven? Read the full paper from Jens P. Goetze, MD, DMSC, Jens F. Rehfeld, MD, DMSC here: #hypertension #cardiovascular

E-Star Biotech is working to reshape how we can help manage hypertension and resulting conditions through activation of key hormones (peptides) produced by the heart, which regulate the body’s blood pressure and metabolic health. Learn more about us at

Miss our recent announcement? E-Star BioTech, a developer of novel peptides for cardiovascular, metabolic, & kidney diseases, has secured new financing & is preparing to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension.

E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment. Mayo Clinic joins ICW Healthcare Ventures as an investor in E-Star. Read full Press Release here: #hypertension #cardiovascular

Atrial natriuretic peptide (ANP) regulates cardiovascular & metabolic functions by promoting vasodilation, reducing aldosterone, & protecting against heart hypertrophy, hypertension, and metabolic syndrome. Learn how E-Star Biotech uses ANP for treatment:

E-Star BioTech, is developing a platform of GC-A agonist for the treatment of cardiovascular and metabolic diseases. Our best-in-class GC-A activator targets the GC-A signaling pathway and the effector molecule cGMP, is currently entering Phase 2 clinical trials.